HOSPITAL CLINICAL DATA NETWORK AND RESEARCH ORGANIZATION COLLABORATION FOR ANALYSIS OF INFECTION BURDEN IN IMMUNOCOMPROMISED PATIENTS IN FRANCE USING REAL-WORLD ELECTRONIC MEDICAL RECORD DATA
Author(s)
Jennifer Dusendang, MPH1, Alexandre Thorel, BSc2, Daniel Poscover, MBA3, Quentin Serrau, MS4, Julien Herbert, MS4, Sylvain Robert, MS5, Leslie Grammatico-Guillon, PhD4;
1Graticule Inc, San Francisco, CA, USA, 2Graticule Inc., Aix-en-Provence, France, 3Graticule Inc., Newton Centre, MA, USA, 4University Hospital of Tours, Tours, France, 5University Hospital of Rennes, Rennes, France
1Graticule Inc, San Francisco, CA, USA, 2Graticule Inc., Aix-en-Provence, France, 3Graticule Inc., Newton Centre, MA, USA, 4University Hospital of Tours, Tours, France, 5University Hospital of Rennes, Rennes, France
Presentation Documents
OBJECTIVES: Although medical institutions collect real-world data during routine clinical practice, this data is not research-ready and typically unavailable to external research partners. Graticule collaborated with the network of the clinical data warehouses (CDWs) of the west region of France (HUGO) to develop a network of research-ready electronic medical record (EMR) data and study real-world infection burden among immunocompromised (IC) patients.
METHODS: The HUGO network deployed CDWs using the eHOP® data model to provide interoperable and quality EMR data across hospitals. A protocol that met research needs, data minimization policies, and ethics requirements was developed for creating a cohort of IC patients from four hospitals. The lead CDW developed a data extraction script, including quality controls and data availability checks, and distributed this script to the network. Following validation, the deidentified cohort from each hospital was securely transferred to the project workspace on the Ouest Data Hub, where the consolidated dataset was converted to the OMOP® Common Data Model for Graticule access and analyses within a secure compute environment.
Patients ≥12 years old were indexed on their first visit between December 2021 and October 2023 in which there was prior or current documentation of an IC condition. Rates of viral respiratory infections during follow-up were described.
RESULTS: A total of 30,150 IC patients qualified for the study, including those with immunosuppressive therapy (56%), hematologic malignancy (27%), organ transplantation (21%), solid tumor (17%), and primary immunodeficiency (6%). Rates of infection were 107.8 cases per 1,000 person-years for SARS-CoV-2, 12.4 for influenza, 9.3 for hMPV, and 5.4 for RSV.
CONCLUSIONS: This IC cohort of 30,150 patients demonstrates that collaborative and flexible partnerships allow for inclusion of EMR data in medical research at a large scale, providing an innovative framework for real-world studies. Benchmarking analyses rank the HUGO network among the most operational infrastructures for real-world research.
METHODS: The HUGO network deployed CDWs using the eHOP® data model to provide interoperable and quality EMR data across hospitals. A protocol that met research needs, data minimization policies, and ethics requirements was developed for creating a cohort of IC patients from four hospitals. The lead CDW developed a data extraction script, including quality controls and data availability checks, and distributed this script to the network. Following validation, the deidentified cohort from each hospital was securely transferred to the project workspace on the Ouest Data Hub, where the consolidated dataset was converted to the OMOP® Common Data Model for Graticule access and analyses within a secure compute environment.
Patients ≥12 years old were indexed on their first visit between December 2021 and October 2023 in which there was prior or current documentation of an IC condition. Rates of viral respiratory infections during follow-up were described.
RESULTS: A total of 30,150 IC patients qualified for the study, including those with immunosuppressive therapy (56%), hematologic malignancy (27%), organ transplantation (21%), solid tumor (17%), and primary immunodeficiency (6%). Rates of infection were 107.8 cases per 1,000 person-years for SARS-CoV-2, 12.4 for influenza, 9.3 for hMPV, and 5.4 for RSV.
CONCLUSIONS: This IC cohort of 30,150 patients demonstrates that collaborative and flexible partnerships allow for inclusion of EMR data in medical research at a large scale, providing an innovative framework for real-world studies. Benchmarking analyses rank the HUGO network among the most operational infrastructures for real-world research.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
P24
Topic
Real World Data & Information Systems
Topic Subcategory
Distributed Data & Research Networks
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Infectious Disease (non-vaccine), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)